Developer docs
API playgroundTry for free, no card

Search company profiles

Sisram Medical Ltd

Full company profile

uuid000e9jm

Namestring
Sisram Medical Ltd
Legal namestring
Sisram Medical Ltd
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Sisram Medical Ltd is an Israel-incorporated, Hong Kong-listed (1696.HK) global medical aesthetics and wellness platform majority-owned by Fosun Pharma (复星医药). Founded in 2013 following the acquisition of Alma — a 25-year incumbent in energy-based medical aesthetics devices — Sisram has expanded into a four-brand ecosystem: Alma (energy-based devices spanning laser, radiofrequency, IPL, and ultrasound modalities for hair removal, skin rejuvenation, body contouring, and clinical indications), LMNT (consumer wellness personal-care devices), Copulla (end-to-end digital dentistry workflow built on BEGO CAD-CAM technology), and an injectables portfolio (Profhilo and Aliaxin distributed from IBSA, plus pipeline assets DaxibotulinumtoxinA from Revance and RZL-012 from Raziel Therapeutics).

Sisram operates an enterprise field-sales motion combined with distributor channels across 110+ countries, with direct offices in Israel (Caesarea HQ), China (Shanghai), Japan, and Thailand. Revenue mechanics are anchored in B2B hardware sales of capital equipment and consumables to surgical, medical, and aesthetic clinics, complemented by injectable product distribution, professional-services revenue from Copulla's digital dentistry platform, and a consumer-direct e-commerce line via LMNT. Pricing is not publicly disclosed but follows standard medical-device enterprise sales cycles with clinical training, marketing, and service support.

The company's strategic posture in 2025–2026 emphasizes APAC localization (China manufacturing facility with Sinmait Medical Technology, Thailand expansion), pipeline broadening via AI-personalized skincare (Universkin by Alma) and premium neuromodulators (DAXXIFY), and commercial-led leadership transition. Fosun Pharma remains the controlling shareholder, providing healthcare-distribution synergies and a strategic anchor for the China and APAC buildout.

Short descriptiontext

Sisram Medical Ltd is an HKEX-listed (1696.HK) global medical aesthetics platform operating the Alma energy-based devices brand, injectables portfolio, Copulla digital dentistry service, and LMNT consumer wellness line across 110+ countries, majority-owned by Fosun Pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersCaesarea, Israel
HQ citystring
Caesarea
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
energy-based aesthetic devices, medical aesthetics solutions, injectable dermal fillers, digital dentistry platform, consumer wellness skincare
Industry4 codes
1Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices)
CodeCRABAAAJPrimaryYes
2Professional Skincare & Facial Treatments
CodeCRABALAFPrimaryNo
3Dermocosmetics & Medical-Grade Skincare
CodeCRABAAAFPrimaryNo
4Dermatology & Aesthetics Pharmaceuticals
CodeHLAIAAAKPrimaryNo
NAICS code4 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
  • Dental Equipment and Supplies Manufacturing339114
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code4 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
  • Dental Equipment & Supplies3843
  • Perfumes, Cosmetics & Other Toilet Preparations2844
Product category
Medical Aesthetics Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Energy-Based Devices (EBD) - Alma
TypeHardware Sales
Description

Sale of medical aesthetics devices and systems for professional clinic use, including systems for hair removal, skin rejuvenation, body contouring, and other aesthetic treatments. Alma operates as a world-leading provider serving surgical, medical aesthetics and beauty markets.

sisram-medical.com
2Injectables
TypeHardware Sales
Description

Distribution and sale of injectable aesthetic products including Profhilo (bio-remodeling), Aliaxin (dermal fillers), and upcoming products like DaxibotulinumtoxinA (neuromodulator) and RZL-012 (fat dissolving).

sisram-medical.com
3Consumer Wellness - LMNT
TypeHardware Sales
Description

Personal care consumer wellness products including energy-based home use devices for skin rejuvenation and self-care routines.

sisram-medical.com
4Digital Dentistry - Copulla
TypeProfessional Services
Description

Digital dentistry services including CAD-CAM dental technology center, digital workflow solutions, and dental products/services.

sisram-medical.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Alma
Description

World-leading provider of energy-based solutions for surgical, medical aesthetics and beauty markets. Offers treatments including hair removal, skin rejuvenation, acne treatment, body contouring, facial contouring, and more.

sisram-medical.com
+3 more records
Core offering1 text field

Sisram Medical develops, manufactures, and distributes a portfolio of energy-based medical aesthetics devices, injectable aesthetic products, consumer personal-care devices, and a digital dentistry service platform under its Alma, LMNT, Copulla, and Injectables brands. Offerings target professional surgical, medical and beauty clinics worldwide with medical-grade treatments for hair removal, skin rejuvenation, body contouring, acne, pigmentation, feminine health, anti-aging, and dental aesthetics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Serving customers in over 110 countries and regions
+1 more record
Product overview1 text field

Sisram Medical Ltd is a global consumer wellness group operating a multi-brand ecosystem focused on medical aesthetics. The company offers four distinct brand lines: Alma (energy-based medical aesthetics devices for clinical treatments), LMNT (consumer personal care/wellness products), Copulla (digital dentistry service platform), and Injectables (dermal fillers, skin boosters, and neuromodulators). Alma serves professional customers with medical-grade treatments for indications including hair removal, skin rejuvenation, body contouring, and feminine health. The company combines energy-based device treatments with injectables therapy for synergistic aging treatment solutions. Sisram was established in 2013 and has been listed on the Hong Kong Stock Exchange since 2017 (1696.HK), with a majority ownership by Fosun Pharma.

Product and service6 records
1Alma Energy-Based Devices
CategoryMedical Aesthetics Devices
Description

World-leading provider of energy-based medical aesthetics devices for surgical, medical aesthetics and beauty markets, covering hair removal, skin rejuvenation, acne treatment, body/facial contouring, skin resurfacing, feminine health, and related clinical indications. Sold to professional clinics and practitioners globally.

2LMNT Personal Care
CategoryConsumer Personal Care Devices
Description

Personal care brand offering light-based and natural-energy consumer wellness devices for at-home skin rejuvenation and daily self-care routines.

3Copulla Digital Dentistry
CategoryDigital Dentistry Platform
Description

End-to-end digital dentistry service platform covering intra-oral scanning through CAD-CAM dental appliance production, enabling cost-effective and efficient aesthetic dentistry workflows for dental practitioners.

4Profhilo Injectable
CategoryInjectable Aesthetic Products
Description

Bio-remodeling injectable composed of stabilized hyaluronic acid designed to remodel multi-layer skin tissue, addressing both causes and symptoms of aging.

5Aliaxin Dermal Fillers
CategoryInjectable Aesthetic Products
Description

Non-invasive dermal filler product line containing ultrapure hyaluronic acid for natural contouring, lifting, and hydration across 12 different facial areas.

6Universkin by Alma
CategoryAI-Powered Personalization Platform
Description

AI-assisted personalized skincare platform that creates customized skincare formulations based on individual skin analysis using AI algorithms to assess skin characteristics.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Sinmait Medical Technology (星迈泰科医疗科技)
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2026-01-25
Description

Partnership to build next-generation manufacturing and innovation hub in China, enhancing local production capabilities. First locally produced Alma Rejuve device rolled off the line in June 2026 at the China manufacturing facility.

sisram-medical.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

IBSA is a multinational pharmaceutical corporation and developer of Profhilo (bio-remodeling injectable) and Aliaxin (dermal fillers). IBSA owns 65 exclusive registered patents worldwide. Sisram distributes IBSA's injectable products.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Revance Aesthetics is developing DaxibotulinumtoxinA for Injection (DAXXIFY/达希斐), a premium long-lasting neuromodulator product. Sisram is bringing this product to markets including China, with NIFDC testing completed in January 2026.

Strategic tierEmergingTypeStrategic or Co-development Partner
Description

Raziel Therapeutics is a clinical-stage pharmaceutical company developing RZL-012, an injectable treatment for aesthetics indications and fat disorders. A single treatment session results in significant and sustained reduction in fat volume.

Strategic tierCoreTypeTechnology or Integration
Description

BEGO provides dental technology for Copulla's global standard CAD-CAM dental technology center, enabling full suite of dental services and products including digital dentistry workflows.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sisram Medical Ltd

Medical Aesthetics Devicessisram-medical.com

Sisram Medical Ltd is an HKEX-listed (1696.HK) global medical aesthetics platform operating the Alma energy-based devices brand, injectables portfolio, Copulla digital dentistry service, and LMNT consumer wellness line across 110+ countries, majority-owned by Fosun Pharma.

What Sisram Medical Ltd does

Sisram Medical Ltd is an Israel-incorporated, Hong Kong-listed (1696.HK) global medical aesthetics and wellness platform majority-owned by Fosun Pharma (复星医药). Founded in 2013 following the acquisition of Alma — a 25-year incumbent in energy-based medical aesthetics devices — Sisram has expanded into a four-brand ecosystem: Alma (energy-based devices spanning laser, radiofrequency, IPL, and ultrasound modalities for hair removal, skin rejuvenation, body contouring, and clinical indications), LMNT (consumer wellness personal-care devices), Copulla (end-to-end digital dentistry workflow built on BEGO CAD-CAM technology), and an injectables portfolio (Profhilo and Aliaxin distributed from IBSA, plus pipeline assets DaxibotulinumtoxinA from Revance and RZL-012 from Raziel Therapeutics).

Sisram operates an enterprise field-sales motion combined with distributor channels across 110+ countries, with direct offices in Israel (Caesarea HQ), China (Shanghai), Japan, and Thailand. Revenue mechanics are anchored in B2B hardware sales of capital equipment and consumables to surgical, medical, and aesthetic clinics, complemented by injectable product distribution, professional-services revenue from Copulla's digital dentistry platform, and a consumer-direct e-commerce line via LMNT. Pricing is not publicly disclosed but follows standard medical-device enterprise sales cycles with clinical training, marketing, and service support.

The company's strategic posture in 2025–2026 emphasizes APAC localization (China manufacturing facility with Sinmait Medical Technology, Thailand expansion), pipeline broadening via AI-personalized skincare (Universkin by Alma) and premium neuromodulators (DAXXIFY), and commercial-led leadership transition. Fosun Pharma remains the controlling shareholder, providing healthcare-distribution synergies and a strategic anchor for the China and APAC buildout.

Sisram Medical Ltd firmographics

Firmographics
Name
Sisram Medical Ltd
Legal name
Sisram Medical Ltd
Website
https://sisram-medical.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Sisram Medical Ltd is an HKEX-listed (1696.HK) global medical aesthetics platform operating the Alma energy-based devices brand, injectables portfolio, Copulla digital dentistry service, and LMNT consumer wellness line across 110+ countries, majority-owned by Fosun Pharma.
Ownership category
akta.pro rank

Sisram Medical Ltd industry classification

Industry
Product category
Medical Aesthetics Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Dental Equipment and Supplies Manufacturing (339114), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Dental Equipment & Supplies (3843), Perfumes, Cosmetics & Other Toilet Preparations (2844)
akta.pro primary industry
Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices) (CRABAAAJ)
akta.pro secondary industries
Professional Skincare & Facial Treatments (CRABALAF), Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

  • Energy-based aesthetic devices
  • Medical aesthetics solutions
  • Injectable dermal fillers
  • Digital dentistry platform
  • Consumer wellness skincare

Where Sisram Medical Ltd is headquartered

Location

Headquarters

HQ city
Caesarea
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

Sisram Medical Ltd business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Energy-Based Devices (EBD) - Alma: Sale of medical aesthetics devices and systems for professional clinic use, including systems for hair removal, skin rejuvenation, body contouring, and other aesthetic treatments. Alma operates as a world-leading provider serving surgical, medical aesthetics and beauty markets.
  2. Injectables: Distribution and sale of injectable aesthetic products including Profhilo (bio-remodeling), Aliaxin (dermal fillers), and upcoming products like DaxibotulinumtoxinA (neuromodulator) and RZL-012 (fat dissolving).
  3. Consumer Wellness - LMNT: Personal care consumer wellness products including energy-based home use devices for skin rejuvenation and self-care routines.
  4. Digital Dentistry - Copulla: Digital dentistry services including CAD-CAM dental technology center, digital workflow solutions, and dental products/services.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Sisram Medical Ltd product offering

Product offering

Core offering

Sisram Medical develops, manufactures, and distributes a portfolio of energy-based medical aesthetics devices, injectable aesthetic products, consumer personal-care devices, and a digital dentistry service platform under its Alma, LMNT, Copulla, and Injectables brands. Offerings target professional surgical, medical and beauty clinics worldwide with medical-grade treatments for hair removal, skin rejuvenation, body contouring, acne, pigmentation, feminine health, anti-aging, and dental aesthetics.

Product overview

Sisram Medical Ltd is a global consumer wellness group operating a multi-brand ecosystem focused on medical aesthetics. The company offers four distinct brand lines: Alma (energy-based medical aesthetics devices for clinical treatments), LMNT (consumer personal care/wellness products), Copulla (digital dentistry service platform), and Injectables (dermal fillers, skin boosters, and neuromodulators). Alma serves professional customers with medical-grade treatments for indications including hair removal, skin rejuvenation, body contouring, and feminine health. The company combines energy-based device treatments with injectables therapy for synergistic aging treatment solutions. Sisram was established in 2013 and has been listed on the Hong Kong Stock Exchange since 2017 (1696.HK), with a majority ownership by Fosun Pharma.

Differentiator

Problem solved

Functional benefit

Brands

  • Alma: World-leading provider of energy-based solutions for surgical, medical aesthetics and beauty markets. Offers treatments including hair removal, skin rejuvenation, acne treatment, body contouring, facial contouring, and more.
  • LMNT
  • Copulla
  • Injectables

Products and services

  • Alma Energy-Based Devices World-leading provider of energy-based medical aesthetics devices for surgical, medical aesthetics and beauty markets, covering hair removal, skin rejuvenation, acne treatment, body/facial contouring, skin resurfacing, feminine health, and related clinical indications. Sold to professional clinics and practitioners globally.
  • LMNT Personal Care Personal care brand offering light-based and natural-energy consumer wellness devices for at-home skin rejuvenation and daily self-care routines.
  • Copulla Digital Dentistry End-to-end digital dentistry service platform covering intra-oral scanning through CAD-CAM dental appliance production, enabling cost-effective and efficient aesthetic dentistry workflows for dental practitioners.
  • Profhilo Injectable Bio-remodeling injectable composed of stabilized hyaluronic acid designed to remodel multi-layer skin tissue, addressing both causes and symptoms of aging.
  • Aliaxin Dermal Fillers Non-invasive dermal filler product line containing ultrapure hyaluronic acid for natural contouring, lifting, and hydration across 12 different facial areas.
  • Universkin by Alma AI-assisted personalized skincare platform that creates customized skincare formulations based on individual skin analysis using AI algorithms to assess skin characteristics.

Quantifiable outcome

  • Serving customers in over 110 countries and regions
  • +1 more outcomes

Companies that use Sisram Medical Ltd

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Sisram Medical Ltd technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Sisram Medical Ltd partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered key, core and emerging.

  • Sinmait Medical Technology (星迈泰科医疗科技)keyStrategic or Co-development Partner · 25 January 2026Partnership to build next-generation manufacturing and innovation hub in China, enhancing local production capabilities. First locally produced Alma Rejuve device rolled off the line in June 2026 at the China manufacturing facility.
  • IBSAcoreStrategic or Co-development PartnerIBSA is a multinational pharmaceutical corporation and developer of Profhilo (bio-remodeling injectable) and Aliaxin (dermal fillers). IBSA owns 65 exclusive registered patents worldwide. Sisram distributes IBSA's injectable products.
  • Revance AestheticskeyStrategic or Co-development PartnerRevance Aesthetics is developing DaxibotulinumtoxinA for Injection (DAXXIFY/达希斐), a premium long-lasting neuromodulator product. Sisram is bringing this product to markets including China, with NIFDC testing completed in January 2026.
  • Raziel TherapeuticsemergingStrategic or Co-development PartnerRaziel Therapeutics is a clinical-stage pharmaceutical company developing RZL-012, an injectable treatment for aesthetics indications and fat disorders. A single treatment session results in significant and sustained reduction in fat volume.
  • BEGOcoreTechnology or IntegrationBEGO provides dental technology for Copulla's global standard CAD-CAM dental technology center, enabling full suite of dental services and products including digital dentistry workflows.

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

Sisram Medical Ltd competitors and assessment

Company assessment

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Customer concentration

Sisram Medical Ltd social profiles

Digital presence

Sisram Medical Ltd financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sisram Medical Ltd leadership team

Management profile

Number of profiles

Profiles6 records

Sisram Medical Ltd subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Sisram Medical Ltd funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sisram Medical Ltd M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sisram Medical Ltd

What does Sisram Medical Ltd do?

Sisram Medical develops, manufactures, and distributes a portfolio of energy-based medical aesthetics devices, injectable aesthetic products, consumer personal-care devices, and a digital dentistry service platform under its Alma, LMNT, Copulla, and Injectables brands. Offerings target professional surgical, medical and beauty clinics worldwide with medical-grade treatments for hair removal, skin rejuvenation, body contouring, acne, pigmentation, feminine health, anti-aging, and dental aesthetics.

Is Sisram Medical Ltd a public or private company?

Sisram Medical Ltd is a public company. It is classified as public and is currently operating.

When was Sisram Medical Ltd founded?

Sisram Medical Ltd was founded in 2013. It employs 1,001 to 5,000 people.

Where is Sisram Medical Ltd based?

Sisram Medical Ltd is headquartered in Caesarea, Israel, in the Middle East region.

How does Sisram Medical Ltd make money?

Four revenue lines are on record. Energy-Based Devices (EBD) - Alma is the primary driver. The others are injectables, consumer Wellness - LMNT and digital Dentistry - Copulla.

Does Sisram Medical Ltd have an API?

No public API is recorded for Sisram Medical Ltd.

What industry is Sisram Medical Ltd in?

Sisram Medical Ltd's product category is Medical Aesthetics Devices. Its primary akta.pro industry code is CRABAAAJ, Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices), with a secondary code of CRABALAF, Professional Skincare & Facial Treatments. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooSisram Medical Ltd (SRAMF) (H1 2026) Earnings Call Highlights: Injectables Surge 54% Offsets ...Sisram Medical reported first-half 2026 revenue of $171.4 million, up 3.6% year over year, with international revenue rising 16.7% to $127 million and APAC share reaching 45%. Injectables revenue jumped 54.2% to $22.2 million, while adjusted net profit fell to $5.04 million from $12 million, and gross margin dropped to 56.7%.Simply Wall StSisram Medical (SEHK:1696) Stock Revenue Growth Masks Sharp Margin CompressionSisram Medical reported a swing to a net loss of US$1.2m for H1 2026 despite revenue growth to US$171.4m, driven by a compression in gross margins from 60.0% to 56.7% and increased operating expenses. The company is investing heavily in its injectables segment, which saw significant growth and expanded market presence in China and APAC, but these gains have not yet offset legacy device weakness and higher costs.Investing.comEarnings call transcript: Sisram Medical H1 2026 profit falls as growth shifts to Asia By Investing.comSisram Medical reported a decline in first-half adjusted net profit to $5.04 million despite a 3.6% revenue increase to $171.4 million, driven by strategic investments in its injectable business in China and the launch of its first pharmaceutical product. The company saw strong growth in international markets outside North America, particularly in Asia-Pacific, while its core energy-based device business faced headwinds in the U.S. market. Management framed the lower profitability as intentional for long-term growth, highlighting accelerating injectable sales and local manufacturing capabilities in Beijing.AInvestSisram Medical H1 revenue USD 171.4 millionSisram Medical reported first-half revenue of USD 171.4 million for the period ending in 2026. The financial figure represents the company's total earnings for the first six months of the fiscal year. No further operational details or strategic implications were provided in the report.PR Newswire APACSisram Medical Delivers Solid 2026 Interim ResultsSisram Medical reported H1 2026 revenue of $171.4 million, up 3.6% year-on-year, with international revenue rising 16.7% and injectables revenue up 54.2% to $22.2 million. Net profit fell to $1.1 million, driven by China injectables investments and North America softness. The company plans to focus on profitability recovery and ecosystem expansion in H2 2026.YahooSisram Medical to Announce 2026 Interim Results on Wednesday, August 19, 2026Sisram Medical Ltd announced it will report its unaudited consolidated interim results for the six months ended June 30, 2026 on Wednesday, August 19, 2026, with an earnings conference call to follow on August 20, 2026. The company's management team, including Chairman Lior Moshe Dayan, CEO Eyal Ben David, and Co-CEO/CFO Jiahong Li, will discuss the financial results via teleconference and webcast with simultaneous interpretation in Chinese and English. The company, majority-owned by Fosram Pharma and listed on the Hong Kong Stock Exchange since 2017, serves customers in over 110 countries and regions.PR NewswireSisram Medical to Announce 2026 Interim Results on Wednesday, August 19, 2026Sisram Medical Ltd announced that it will report its unaudited consolidated interim results for the six months ended June 30, 2026 on August 19, 2026. The company's management will host an earnings conference call on August 20, 2026 to discuss these financial results.YahooSisram Medical Launches Titanium Prime Treatment Concept in Hong Kong SARSisram Medical Ltd announced the official launch of its Titanium Prime treatment concept in Hong Kong SAR on August 5, 2026, integrating two flagship energy-based device platforms—Alma PrimeX and Soprano Titanium Special Edition—powered by Tri-Energy Synergy technology. The new protocol combines laser, radiofrequency, and ultrasound modalities via the BTS² Methodology to deliver multidimensional anti-aging and skin rejuvenation outcomes across multiple tissue depths. The launch represents Sisram's strategic pivot from a standalone device supplier to a comprehensive multi-technology aesthetic platform, positioning the company to capitalize on the market shift toward integrated multi-platform treatment regimens.PR Newswire APACSisram Medical Launches Titanium Prime Treatment Concept in Hong Kong SARSisram Medical Ltd launched its Titanium Prime treatment concept in Hong Kong SAR on August 5, 2026, integrating two flagship energy-based device platforms—Alma PrimeX and Soprano Titanium Special Edition—under a unified Tri-Energy Synergy protocol. The new concept combines laser, radiofrequency, and ultrasound modalities to target multiple skin layers for anti-aging and rejuvenation treatments, representing Sisram's strategic pivot from a standalone device supplier toward an integrated multi-technology service model. The company plans to use the Hong Kong SAR rollout as a benchmark for expanding combined treatment strategies across key Asia-Pacific markets.PR NewswireSisram Medical Launches Titanium Prime Treatment Concept in Hong Kong SARSisram Medical Ltd (1696.HK) officially launched its Titanium Prime treatment concept in Hong Kong SAR on August 4, 2026, integrating two flagship energy-based device platforms—Alma PrimeX and Soprano Titanium Special Edition—under its proprietary Tri-Energy Synergy technology and BTS² Methodology. The combined protocol uses laser, radiofrequency, and ultrasound modalities to target multiple tissue depths for anti-aging and skin rejuvenation, representing the company's strategic evolution from a standalone device supplier to an integrated multi-technology aesthetic platform. The company views Hong Kong SAR as a pivotal hub to incubate and scale the concept across key APAC markets, with plans to use the successful rollout as a benchmark for regional expansion.